Komipharm International Co (XKRX:041960) ROCE % : 51.33% (As of Sep. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Komipharm International Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Komipharm International Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 51.33%.

Komipharm International Co ROCE % Historical Data

The historical data trend for Komipharm International Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Komipharm International Co ROCE % Chart

Komipharm International Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-12.15

-2.72

-4.97

-6.57

-4.65

Komipharm International Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-4.47	-2.68	6.18	32.49	51.33

Komipharm International Co ROCE % Calculation

Komipharm International Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3187.508	/	( ( (111750.977 - 41047.474)	+	(118597.807 - 52228.262) )	/ 2 )
	=	-3187.508	/	( (70703.503	+	66369.545)	/ 2 )
	=	-3187.508	/	68536.524
	=	-4.65 %

Komipharm International Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	38780.084	/	( ( (123043.99 - 51221.592)	+	(132557.882 - 53293.024) )	/ 2 )
	=	38780.084	/	( ( 71822.398	+	79264.858 )	/ 2 )
	=	38780.084	/	75543.628
	=	51.33 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Komipharm International Co (XKRX:041960) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Komipharm International Co ROCE % Related Terms

Thank you for viewing the detailed overview of Komipharm International Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Komipharm International Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Komipharm International Co Ltd (XKRX:041960) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

1236-6 Jungwang-Dong, Sihung, Gyeonggi, KOR, 429-450

Website

http://www.komilab.co.kr

Komipharm International Co Ltd is involved in the healthcare sector based in Korea. Its core business includes development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The company produces its products under two divisions: veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle. The other division is made up of veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis and swine erysipelas.

Komipharm International Co Headlines

No Headlines